| ADAM28 |
Overexpression correlates with cell proliferation and lymph node metastasis |
[35] |
|
Serological and histochemical marker for NSCLC |
[36] |
| ANGPT1 |
Role in the prognosis of patients with oral squamous cell cancer |
[37] |
| CA2 |
Downregulated in gastric cancer and proposed as an independent prognostic factor for patient survival |
[38] |
| CD24 |
Expression at early stages of breast cancer indicates a highly invasive tumor |
[39] |
| DAB2 |
An important tumor suppressor, frequently downregulated in various tumors |
[40] |
| HOXA5 |
Downregulation is associated with poor prognosis in NSCLC |
[41] |
|
Shown to prevent tumor progression and metastasis in colon cancer |
[42] |
| IL6 |
SNP associated with risk of multiple cancers |
[43] |
| KLF10 |
Potential clinical predictor for progression of pancreatic cancer |
[44] |
| MCL1 |
Key molecule for acquiring epithelial-to-mesenchymal transition-associated chemo-resistance in NSCLC |
[45] |
| NES |
Marker of cancer stem cells |
[46] |
| NUSAP1 |
Encodes protein that is proposed biomarker for prostate cancer recurrence |
[47] |
| PDZD2 |
Shown to induce senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53 |
[48] |
| RGS17 |
Induces tumor cell proliferation lung and prostate cancers |
[49] |
|
Regulator of cell survival and chemoresistance in ovarian cancer |
[50] |
| RUNX1T1 |
Predictor of liver metastasis in pancreatic endocrine tumours |
[51] |
|
Associated with proliferation and senescence inhibition in t(8;21)-positive leukaemic cells |
[52] |
| SELC14L1 |
Proposed marker for predicting prognosis and progression of prostate cancer |
[53] |
| SEMA5A |
Over-expressed pancreatic cancer cells, regulates tumorigenesis, proliferation, invasion and metastasis, and serve as a target for diagnosis and treatment of pancreatic cancer |
[54] |
| SEPP1 |
Inversely related to pancreatic cancer risk |
[55] |
